12 February 2026 - The US FDA has approved drug labelling changes to six menopausal hormone therapy products, also known as hormone replacement therapy, to clarify risk considerations for these drugs. 

Specifically, risk statements related to cardiovascular disease, breast cancer and probable dementia were removed from the “boxed warning,” the agency’s most prominent safety-related warning.

Read FDA press release